Serum periostin in patients hospitalized for COPD exacerbations

•Serum periostin is a surrogate biomarker of Th2 response in asthma.•Periostin levels on COPD hospitalization were elevated compared to discharge.•Periostin was not a good predictor of future risk for hospitalization or mortality. Serum periostin has been proposed as a surrogate biomarker of Th2 inf...

Full description

Saved in:
Bibliographic Details
Published in:Cytokine (Philadelphia, Pa.) Pa.), 2017-05, Vol.93, p.51-56
Main Authors: Konstantelou, Elissavet, Papaioannou, Andriana I., Loukides, Stelios, Bartziokas, Konstantinos, Papaporfyriou, Anastasia, Papatheodorou, Georgios, Bakakos, Petros, Papiris, Spyros, Koulouris, Nikolaos, Kostikas, Konstantinos
Format: Article
Language:English
Subjects:
Aged
Biomarkers - blood
Cell Adhesion Molecules - blood
COPD exacerbations
Female
Future risk
Hospitalization
Humans
Male
Periostin
Pulmonary Disease, Chronic Obstructive - blood
Pulmonary Disease, Chronic Obstructive - therapy
Th2 inflammatory response
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Serum periostin is a surrogate biomarker of Th2 response in asthma.•Periostin levels on COPD hospitalization were elevated compared to discharge.•Periostin was not a good predictor of future risk for hospitalization or mortality. Serum periostin has been proposed as a surrogate biomarker of Th2 inflammatory response in patients with asthma, but its predictive role in hospitalized patients with COPD has not been evaluated. The aim of the present observational prospective cohort study was to evaluate the possible role of serum periostin as predictor of outcome in COPD patients hospitalized for AECOPD. Serum periostin was measured on admission and at discharge in patients admitted to the hospital for a COPD exacerbation. Patients were followed-up for 1year for future exacerbations, hospitalizations and mortality. 155 consecutive patients admitted to the hospital for AECOPD were included to the study. Periostin levels on admission were elevated compared to discharge [34.7 (25.2–52.2) vs. 25.9 (17.4–41.0) ng/mL, p=0.003], but serum periostin levels did not differ between patients with or without prolonged hospitalization, or those who required non-invasive ventilation, intubation, or died during hospitalization. Frequent exacerbators had higher serum periostin levels at the time of discharge compared to non-frequent exacerbators [37.9 (26.6, 64.5) vs. 23.9 (16.2, 37.9), p
ISSN:1043-4666
1096-0023
DOI:10.1016/j.cyto.2017.05.007